Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints

R. Meier, D. Blöch, C. Cotrutz, Alan Beckman, G. Henning, S.A. Woodhouse, Shirnett Williamson, Najeeb Mohideen, John Dombrowski, Robert L. Hong,

International Journal of Radiation Oncology*Biology*Physics · 2018 · 123 citations · 30 references

DOIFull text

Open access

Abstract

Dose-escalated prostate SBRT was administered with minimal toxicity in this multi-institutional study. Relapse rates compared favorably with historical controls. SBRT is a suitable option for LR and IR prostate cancer.

References

30